Analytical Data
-
基因名
HMGCL
- Application
-
别名
HMGCL;Hydroxymethylglutaryl-CoA lyase. mitochondrial
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P35914
-
表达区间
28-325aa
-
氨基酸序列
MTLPKRVKIVEVGPRDGLQNEKNIVSTPVKIKLIDMLSEAGLSVIETTSF VSPKWVPQMGDHTEVLKGIQKFPGINYPVLTPNLKGFEAAVAAGAKEVVI FGAASELFTKKNINCSIEESFQRFDAILKAAQSANISVRGYVSCALGCPY EGKISPAKVAEVTKKFYSMGCYEISLGDTIGVGTPGIMKDMLSAVMQEVP LAALAVHCHDTYGQALANTLMALQMGVSVVDSSVAGLGGCPYAQGASGNL ATEDLVYMLEGLGIHTGVNLQKLLEAGNFICQALNRKTSSKVAQATCKLH HHHHH
-
分子量
33 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HMGCL (3-hydroxy-3-methylglutaryl-CoA lyase) is an essential enzyme in the ketogenesis and leucine catabolism pathways, facilitating the conversion of HMG-CoA to acetoacetate and acetyl-CoA. Deficiencies in HMGCL can lead to significant metabolic disorders, including organic acidemia and severe hypoketotic hypoglycemia, which pose serious health risks, particularly in neonates. The necessity for a robust understanding of HMGCL both in terms of its structure and function has spurred research efforts into recombinant protein production. Recombinant HMGCL allows for the detailed study of enzyme kinetics, structure-function relationships, and potential therapeutic interventions. Furthermore, the production of this enzyme in a controlled system can facilitate the development of diagnostic tools and therapeutic strategies for managing related metabolic disorders. Advances in molecular biology techniques, such as CRISPR and gene cloning, have enabled researchers to produce recombinant HMGCL in various host systems, including bacteria and yeast, thereby enhancing its availability for both basic and applied research. The insights gained from the study of recombinant HMGCL not only contribute to our understanding of metabolic pathways but also provide a foundation for potential clinical applications in treating metabolic diseases associated with HMGCL deficiency.
